José Trevejo, MD, PhD, has been named Chief Medical Officer of Tarsus Pharmaceuticals. Dr. Trevejo has more than 20 years of experience in clinical development of novel treatments for serious diseases.

Eyenovia has made changes to its Board of Directors.

Joel Prieve has been named Senior Vice President, Commercial Operations at Outlook Therapeutics, which is working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal diseases.

Spark Therapeutics, a part of the Roche Group, announced that Ron Philip, the company's COO, will take over as CEO from co-founder Jeffrey D. Marrazzo. Mr. Marrazzo, who joined the company as a co-founder in 2013, will step down on April 1.

Tarsus Pharmaceuticals announced that Elizabeth Yeu, MD, has been appointed to its Board of Directors. Dr. Yeu will continue to serve as the company’s Chief Medical Advisor.

BRIM Biotechnology has entered OTC trading in Taiwan on June 23, 2022. Established in 2013, BRIM is a clinical-stage company developing novel regenerative therapies to help combat and cure ophthalmology and degenerative joint diseases.

RxSight welcomes Tamara R. Fountain, MD, and Shweta Singh Maniar into its Board of Directors.

Dutch Evmann Investments Holding, the parent company of VSY Biotechnology GmbH and Alsanza Medizintechnik und Pharma GmbH, organized its 2022 Global Leadership Meeting last week in line with its strategic plans to become a Unicorn company.

Oyster Point Pharma announced it will implement an operating expense streamlining plan that will include a reduction of employee and non-employee expenses across the organization.

Euclid Vision, formerly Euclid Systems, has announced its acquisition of Visionary Optics, a specialty scleral contact lens design and distribution company.